Method for treating conditions associated with hyperproliferating cells comprising combined administration of a cannabinoid receptor agonist and radiation therapy
Inventors
Dumoulin-White, Roger • Mandel, Arkady
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11793818-B2
Publication Date
2023-10-24
Expiration Date
Abstract
Disclosed is a method for treating a condition associated with hyperproliferating cells, the method including the steps of administering to a subject having the condition a composition including at least one cannabinoid receptor agonist, optionally administering to the subject a photodynamic compound, and administering radiation to the subject in whom the at least one cannabinoid receptor agonist is present so as to treat the condition.
Core Innovation
The invention relates to treating cancer by administering a cannabinoid receptor agonist and a photodynamic compound to a subject having cancer cells. The cannabinoid receptor agonist is administered as part of a composition, and the photodynamic compound is administered to the subject.
Radiation is administered to the subject in whom the cannabinoid receptor agonist and the photodynamic compound are present. The radiation activates the photodynamic compound to generate radicals and reactive oxygen species to destroy the cancer cells to treat the cancer.
In disclosed embodiments, the cannabinoid receptor agonist includes delta9-tetrahydrocannabinol (delta9-THC) and/or cannabidiol, and radiation may include infrared light, visible light, X-rays, or other ionizing radiation. The photodynamic compound can be a metallosupramolecular complex and may be associated with a metal-binding glycoprotein such as transferrin (e.g., RUTHERRIN), and the disclosure describes synergistic effects and radio-enhancement with radiation.
Claims Coverage
The provided independent claims cover a multi-agent cancer-treatment method in which a cannabinoid receptor agonist and a photodynamic compound are administered before radiation that activates the photodynamic compound to generate radicals and reactive oxygen species or otherwise destroy cancer cells while the agents are present. Across the claim set provided, two principal inventive feature groupings are recited.
Cannabinoid receptor agonist plus photodynamic compound to a subject having cancer cells
Administering to a subject having cancer cells a composition comprising at least one cannabinoid receptor agonist and administering to the subject a photodynamic compound.
Radiation activation of the photodynamic compound while agonist and photodynamic compound are present
Administering radiation to the subject in whom the at least one cannabinoid receptor agonist and the photodynamic compound are present so as to activate the photodynamic compound to generate at least one of radicals and reactive oxygen species to destroy the cancer cells to treat the cancer.
Destroy cancer cells with cannabinoid receptor agonist and photodynamic compound present during radiation
Administering radiation to the subject in whom the at least one cannabinoid receptor agonist and the photodynamic compound are present so as to destroy the cancer cells to treat the cancer.
Across the independent claims, the method requires administering a cannabinoid receptor agonist and a photodynamic compound to a subject having cancer cells, and administering radiation to the subject while both agents are present so that the photodynamic compound is activated to generate radicals and reactive oxygen species to destroy cancer cells to treat the cancer.
Stated Advantages
Treating cancer by destroying cancer cells.
Synergistic effects and radio-enhancement with radiation.
Documented Applications
Treating cancer using a cannabinoid receptor agonist and a photodynamic compound activated by radiation.
Interested in licensing this patent?